Loading…
Collaboration with cannabinoid drug-development experts announced.
Splash Beverage Group, Inc. (NYSE: SBEV) has announced a partnership with a veteran cannabinoid drug-development team to progress CannEpil®, a cannabinoid-based treatment, through the FDA Veterinary Pathway. This strategic collaboration aims to leverage the expertise of both parties to enhance the development and potential approval of CannEpil® for veterinary use.
The partnership will focus on navigating the regulatory requirements and clinical trials necessary for FDA approval. Splash Beverage Group intends to utilize its resources and market presence to support the development process, while the cannabinoid drug-development team will provide scientific and technical guidance.
As of the latest company context, Splash Beverage Group has a free float of 566,097 shares and 6,300,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.